PMID- 9126798
OWN - NLM
STAT- MEDLINE
DCOM- 19970730
LR  - 20190817
IS  - 0168-8278 (Print)
IS  - 0168-8278 (Linking)
VI  - 26
IP  - 4
DP  - 1997 Apr
TI  - Identification of an autoantibody against alpha-enolase in primary biliary 
      cirrhosis.
PG  - 845-51
AB  - BACKGROUND: Primary biliary cirrhosis is a chronic cholestatic liver disease in 
      which autoreactive T cells may play an important role in the destruction of 
      intrahepatic bile ducts. However, target antigens remain unknown. 
      Alpha-enolase-derived peptide binds to human leukocyte antigen (HLA)-DR8, which 
      is implicated in the development of primary biliary cirrhosis in Japanese 
      patients. Partial homology between alpha-enolase and the inner lipoyl domain of 
      E2 component of pyruvate dehydrogenase (PDH-E2) is also observed. METHODS: Using 
      alpha, beta and gamma enolase isozymes obtained from humans and/or rabbits, we 
      examined serum samples of 56 patients with primary biliary cirrhosis, 19 
      autoimmune hepatitis, 38 acute and chronic viral hepatitis and 36 healthy 
      subjects by immunoblotting. RESULTS: Anti-alpha-enolase antibody was present in a 
      significantly higher percentage of patients with primary biliary cirrhosis (16 of 
      56, 28.6%) and autoimmune hepatitis (6 of 19, 31.6%) than in normal subjects 
      (p<0.005, p<0.01, respectively). Antibodies against beta and gamma-enolases were 
      not detected in any serum sample. Although there was no significant correlation 
      between the presence of anti-alpha-enolase antibody and clinical features of 
      primary biliary cirrhosis, the mortality rate associated with hepatic failure in 
      patients with positive autoantibody was significantly higher than that of 
      antibody-negative PBC patients (6 of 16, 37.5% vs 5 of 40, 12.5%, p<0.05). 
      CONCLUSIONS: Since alpha-enolase is expressed on the cell surface, our data 
      suggest that the immunological reaction to alpha-enolase might be involved in 
      biliary epithelial destruction and be relevant to the disease progression.
FAU - Akisawa, N
AU  - Akisawa N
AD  - The First Department of Internal Medicine, Kochi Medical School, Nankoku, Japan.
FAU - Maeda, T
AU  - Maeda T
FAU - Iwasaki, S
AU  - Iwasaki S
FAU - Onishi, S
AU  - Onishi S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Hepatol
JT  - Journal of hepatology
JID - 8503886
RN  - 0 (Autoantibodies)
RN  - 0 (Isoenzymes)
RN  - 0 (Pyruvate Dehydrogenase Complex)
RN  - EC 4.2.1.11 (Phosphopyruvate Hydratase)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Antibody Specificity
MH  - Autoantibodies/analysis/*immunology
MH  - Autoimmune Diseases/immunology
MH  - Chronic Disease
MH  - Female
MH  - Hepatitis/immunology
MH  - Hepatitis, Viral, Human/immunology
MH  - Humans
MH  - Immunoblotting
MH  - Isoenzymes/*immunology
MH  - Liver Cirrhosis, Biliary/*immunology/mortality/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Phosphopyruvate Hydratase/*immunology
MH  - Pyruvate Dehydrogenase Complex/immunology
MH  - Rabbits
MH  - Reference Values
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - S0168-8278(97)80251-6 [pii]
AID - 10.1016/s0168-8278(97)80251-6 [doi]
PST - ppublish
SO  - J Hepatol. 1997 Apr;26(4):845-51. doi: 10.1016/s0168-8278(97)80251-6.